Your browser doesn't support javascript.
loading
Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis.
Martínez-Barriocanal, Águeda; Arcas-García, Andrea; Magallon-Lorenz, Miriam; Ejarque-Ortíz, Aroa; Negro-Demontel, María Luciana; Comas-Casellas, Emma; Schwartz, Simo; Malhotra, Sunny; Montalban, Xavier; Peluffo, Hugo; Martín, Margarita; Comabella, Manuel; Sayós, Joan.
Afiliación
  • Martínez-Barriocanal Á; CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Arcas-García A; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBBER-BBN), Instituto de Salud Carlos III, Barcelona, Spain.
  • Magallon-Lorenz M; CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Ejarque-Ortíz A; CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Negro-Demontel ML; CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Comas-Casellas E; Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Schwartz S; Neuroinflammation and Gene Therapy Laboratory, Institut Pasteur Montevideo, Montevideo, Uruguay.
  • Malhotra S; CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Montalban X; CIBBIM-Nanomedicine-Drug Delivery and Targeting Group. Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Peluffo H; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBBER-BBN), Instituto de Salud Carlos III, Barcelona, Spain.
  • Martín M; Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Comabella M; Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Sayós J; Neuroinflammation and Gene Therapy Laboratory, Institut Pasteur Montevideo, Montevideo, Uruguay.
Sci Rep ; 7(1): 13544, 2017 10 19.
Article en En | MEDLINE | ID: mdl-29051512
ABSTRACT
Herein, we have used bioinformatics tools to predict five clusters defining ligand-binding sites on the extracellular domain of human CD300b receptor, presumably involved in the formation of both homodimers and heterodimers with other CD300 family members. Site-directed mutagenesis revealed residues glutamic acid 28 and glutamine 29 in cluster 5 to be necessary for the formation of CD300b complexes. Surprisingly, the disruption of cluster 2 and 4 reconstituted the binding capability lost by the mutation of residues glutamic acid 28 to alanine, glutamine 29 to alanine (E28A-Q29G). We identified a missense mutation arginine 33 to glutamine (R33Q) in CD300f by direct sequencing of exon 2 in peripheral blood samples from 50 patients with multiple sclerosis (MS). Levels of expression of CD300f were almost undetectable on monocytes from the patient bearing the R33Q mutation compared with healthy individuals. Whereas R33Q mutation had no effect in the formation of CD300f complexes, the inhibition of protein synthesis with cycloheximide indicated that CD300f R33Q is less stable than native CD300f. Finally, we report that the levels of expression of CD300f on the surface of classical and intermediate monocytes from MS patients are significantly lower when compared to the same cell populations in healthy individuals.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores Inmunológicos / Esclerosis Múltiple Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Animals / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores Inmunológicos / Esclerosis Múltiple Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Animals / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: España